SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2018 / Cilt: 48 - Sayı: 4

Methodology of a new inflammatory arthritis registry: TReasure

Levent KILIÇ
Muhammet ÇINAR
Aşkın ATEŞ
Ömer KARADAĞ
Ali İhsan ERTENLİ
Ali ŞAHİN
Hüseyin Ediz DALKILIÇ
Cemal BES
Ayşe Bahar KELEŞOĞLU DİNÇER
Veli YAZISIZ
Orhan KÜÇÜKŞAHİN
Ender TERZİOĞLU
Nilüfer ALPAY KANITEZ
Hakan EMMUNGİL
Yavuz PEHLİVAN
Gezmiş KİMYON
Sedat KİRAZ
Rıdvan MERCAN
Burc
Pages
856–861
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Finally, ahigh-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritispatients.
📊
Key Findings & Data:Pharmaceutical companies thatoperate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support theTReasure registry.
💡
Conclusion & Impact:Finally, ahigh-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA.
🔬Design:Review & Systematic Survey
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Abstract

Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritispatients. This article reviews the methodology and objectives of the TReasure registry established to collect data from rheumatoidarthritis (RA) and spondyloarthritis (SpA) patients.Methodology: Fifteen rheumatology centers in Turkey will contribute data to the TReasure database. The actual proprietor of thedatabase is the Hacettepe Rheumatology Association (HRD) and Hacettepe Financial Enterprises. Pharmaceutical companies thatoperate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support theTReasure registry. TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure)with their unique identifier and passwords provided for data entry and access. TReasure records demographic and clinical features,comorbidities, radiology and laboratory results, measures of disease activity, and treatment data.Discussion: TReasure will provide us with various types of data, such as a cross-sectional view of the current nationwide status of thepatients currently receiving these treatments, and retrospective data as much as allowed by the participating centers’ records. Finally, ahigh-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA.

🔖

Cite This Article

KILIÇ, L., ÇINAR, M., ATEŞ, A., KARADAĞ, Ö., ERTENLİ, A. İ., ŞAHİN, A., DALKILIÇ, H. E., BES, C., DİNÇER, A. B. K., YAZISIZ, V., KÜÇÜKŞAHİN, O., TERZİOĞLU, E., KANITEZ, N. A., EMMUNGİL, H., PEHLİVAN, Y., KİMYON, G., KİRAZ, S., MERCAN, R., Burc, B. (2022). Methodology of a new inflammatory arthritis registry: TReasure. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 4, 856–861. https://ajindex.com/articles/610308

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, Bertilsson L, Cöster L, Jacobsson LT, Lindblad S et al. Antitumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009; 68: 648-653.
  2. Lapadula G, Ferraccioli G, Ferri C, Punzi L, Trotta F. GISEA: An Italian biological agents registry in rheumatology. Reumatismo 2011; 63: 155-164.
  3. Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 2011; 50: 222-229.
  4. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, Listing J. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70: 1914- 1920. de la Vega M, da Silveira de Carvalho HM, Ventura Rios L, Goycochea Robles MV, Casado GC. The importance of rheumatology biologic registries in Latin America. Rheumatol Int 2013; 33: 827-835.
  5. Ibfelt EH, Jensen DV, Hetland ML. The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO. Clin Epidemiol 2016; 8: 737-742.
  6. Mercer LK, Galloway JB, Lunt M, Davies R, Low AL, Dixon WG, Watson KD; BSRBR Control Centre Consortium, Symmons DP, Hyrich KL. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2017; 76: 497-503.
  7. Strand V, Miller P, Williams SA, Saunders K, Grant S, Kremer J. Discontinuation of biologic therapy in rheumatoid arthritis: analysis from the Corrona RA Registry. Rheumatol Ther 2017; 4: 489-502. Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford) 2012; 51 (Suppl. 6): vi37-43. Erden A, Kılıç L, Karadağ Ö, Akdoğan A, Bilgen ŞA, Kıraz S, Ertenli İ, Kalyoncu U. Ankilozan spondilit hastalarında golimumab kullanımı: HÜR-BİO/Spondiloartrit gerçek yaşam deneyimi. RAED Dergisi 2015; 7: 6-9 (in Turkish). Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
  8. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnb